Estradiol Gel — Systemic Estrogen in a Daily Topical Format

Route: Topical transdermal gel, applied once daily.

• Apply to clean, dry, intact skin — commonly the upper arm, inner forearm, or thigh.
• Use the prescribed volume or number of pump actuations per the prescriber's instructions.
• Spread gently over a 5–7 cm area; allow 1–2 minutes to dry before dressing.
• Do not apply to the breast, face, or irritated/broken skin.
• Wash hands thoroughly after application.
• Avoid skin-to-skin contact with others (particularly children, men, and pets) until gel is fully absorbed and dry.

The prescribing clinician determines the specific concentration and dose based on symptom severity, serum estradiol targets, and patient history. General dosing principles for transdermal estradiol gel:

• Start low and titrate — initiate at the lowest effective dose to control symptoms.
• Serum estradiol monitoring at 4–8 weeks guides dose adjustment; target physiologic replacement levels.
• Women with an intact uterus require concurrent progestogen to prevent endometrial hyperplasia.
• The lowest effective dose for the shortest clinically appropriate duration is recommended per established hormonal therapy principles.

• Estradiol (transdermal): 17β-estradiol absorbed through the skin enters systemic circulation without first-pass hepatic metabolism, producing physiologic serum estradiol levels. Binds nuclear ERα and ERβ causing dimerization, translocation to the nucleus, and binding to estrogen response elements (EREs), regulating gene transcription governing thermoregulation, bone remodeling (inhibiting osteoclast activity), vaginal epithelial cell proliferation, serotonergic tone (mood and cognition), endothelial nitric oxide production, and skin collagen synthesis. Non-genomic rapid signaling occurs via membrane-bound ERs (GPER) through PI3K, MAPK/ERK pathways.

Clinical Context: Compounded transdermal estradiol gel is a systemic hormone therapy option for peri- and postmenopausal women with vasomotor symptoms, genitourinary syndrome of menopause, mood and sleep disturbance, osteoporosis prevention, and sexual dysfunction attributable to estrogen deficiency. The gel format provides consistent once-daily dosing, adjustable concentration, and avoids first-pass hepatic metabolism — a pharmacokinetic advantage for patients at higher hepatic or thromboembolic risk compared to oral estrogen. ACOG acknowledges that compounded bioidentical hormone preparations have not been evaluated for safety and efficacy in the same way as FDA-approved products.

Monitoring:

• Serum estradiol at 4–8 weeks; adjust dose based on symptoms and laboratory targets.
• Endometrial surveillance and concurrent progestogen in women with intact uterus.
• Annual mammography; clinical breast exam.
• Blood pressure; lipids as clinically indicated.

Contraindications:

• Estrogen-dependent malignancies (breast, endometrial).
• Undiagnosed abnormal vaginal/uterine bleeding.
• Active or history of VTE, PE, or arterial thromboembolic events.
• Active liver disease or hepatic impairment.
• Known thrombophilic disorders.
• Pregnancy.

Warnings & Precautions:

• Endometrial safety: unopposed estrogen requires concurrent progestogen in non-hysterectomized patients.
• Breast cancer risk with prolonged use.
• Thromboembolic risk: lower than oral route but not absent.
• Transfer risk: allow gel to dry; wash hands.

Drug Interactions:

• CYP3A4 inducers (rifampin, carbamazepine, phenytoin): reduce estradiol exposure.
• CYP3A4 inhibitors: increase exposure.
• Thyroid hormone: estrogen increases TBG — monitor free thyroid hormone.

Common Side Effects: Breast tenderness, headache, nausea, application site reactions, bloating, breakthrough bleeding, mood changes.

Store at controlled room temperature (20–25°C / 68–77°F). Do not freeze. Keep pump tightly capped and away from light and heat. Store out of reach of children and protect from unintended exposure to household members. Use before the beyond-use date assigned by Genesis Compounding.

What is the advantage of a gel over a patch or pill?

Gel allows fine dosage adjustment (by varying number of pump actuations or volume applied), avoids adhesive-related skin irritation common with patches, and bypasses hepatic first-pass metabolism unlike oral tablets. It provides flexibility in dosing while delivering consistent systemic estrogen levels.

How is the concentration in this gel determined?

The prescriber specifies the concentration based on the patient's clinical needs, baseline hormone levels, and therapeutic goals. Compounding allows precise, patient-specific concentrations that may not be available in commercially approved products.

When should I expect symptom improvement?

Vasomotor symptoms (hot flashes, night sweats) often begin to improve within 2–4 weeks of initiation. Full therapeutic benefit may take 8–12 weeks. Serum estradiol monitoring helps confirm absorption and guide dose adjustment.

Do I need to use progesterone with this gel?

Yes, if you have an intact uterus — unopposed estrogen increases the risk of endometrial hyperplasia and cancer. The prescriber will determine whether and what type of progestogen to co-prescribe based on your individual history.

Is this product FDA-approved?

FDA-approved estradiol gel products exist (e.g., EstroGel® 0.06%). This Genesis Compounding preparation is a patient-specific 503A compounded product prepared under prescriber direction and is not itself FDA-approved as a compounded preparation.